BG00011, a humanized αvβ6-specific monoclonal antibody, has completed the Phase 2A study in IPF and demonstrated a decrease of active TGF-β signaling as evidenced by dose-dependent reductions in p-SMAD2 in bronchoalveolar lavage cells from patients without serious adverse events (NCT01371305) (Table 1), highlighting the therapeutic potential of targeting integrins and their activation of TGF-β signaling in fibrotic diseases. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.